Endometrial Cancer - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 265 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Endometrial Cancer - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Endometrial Cancer - Pipeline Review, H1 2015', provides an overview of the Endometrial Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Endometrial Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Endometrial Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Endometrial Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Endometrial Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Endometrial Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Endometrial Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Endometrial Cancer Overview 8
Therapeutics Development 9
Pipeline Products for Endometrial Cancer - Overview 9
Pipeline Products for Endometrial Cancer - Comparative Analysis 10
Endometrial Cancer - Therapeutics under Development by Companies 11
Endometrial Cancer - Therapeutics under Investigation by Universities/Institutes 15
Endometrial Cancer - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Endometrial Cancer - Products under Development by Companies 19
Endometrial Cancer - Products under Investigation by Universities/Institutes 22
Endometrial Cancer - Companies Involved in Therapeutics Development 23
Acceleron Pharma, Inc. 23
Aeterna Zentaris Inc. 24
Ariad Pharmaceuticals, Inc. 25
Arno Therapeutics, Inc. 26
ArQule, Inc. 27
AstraZeneca Plc 28
AVEO Pharmaceuticals, Inc. 29
BioMarin Pharmaceutical Inc. 30
Boehringer Ingelheim GmbH 31
Critical Outcome Technologies Inc. 32
Daiichi Sankyo Company, Limited 33
Eisai Co., Ltd. 34
Esperance Pharmaceuticals, Inc. 35
Exelixis, Inc. 36
Farmsintez 37
Galena Biopharma, Inc. 38
Genentech, Inc. 39
Genmab A/S 40
GlaxoSmithKline Plc 41
Gradalis Inc. 42
ImmunoGen, Inc. 43
Incyte Corporation 44
Karyopharm Therapeutics, Inc. 45
Merck & Co., Inc. 46
Merck KGaA 47
Millennium Pharmaceuticals, Inc. 48
Novartis AG 49
OncoHoldings, Inc. 50
Oncothyreon Inc. 51
Otsuka Holdings Co., Ltd. 52
Pharma Mar, S.A. 53
Puma Biotechnology, Inc. 54
Sanofi 55
Scancell Holdings Plc 56
Shenogen Pharma Group Ltd. 57
Endometrial Cancer - Therapeutics Assessment 58
Assessment by Monotherapy Products 58
Assessment by Combination Products 59
Assessment by Target 60
Assessment by Mechanism of Action 64
Assessment by Route of Administration 67
Assessment by Molecule Type 69
Drug Profiles 71
(ponatinib hydrochloride + ridaforolimus) - Drug Profile 71
���Pb-TCMC-Trastuzumab - Drug Profile 72
AEZS-125 - Drug Profile 74
afuresertib hydrochloride + trametinib dimethyl sulfoxide - Drug Profile 75
ARQ-092 - Drug Profile 76
AV-203 - Drug Profile 77
AZD-2014 - Drug Profile 78
AZD-5363 - Drug Profile 80
buparlisib hydrochloride - Drug Profile 82
cabozantinib s-malate - Drug Profile 86
cancer vaccine - Drug Profile 89
Cell Therapy for Oncology - Drug Profile 91
CLR-457 - Drug Profile 92
COTI-2 - Drug Profile 93
cridanimod - Drug Profile 96
dalantercept - Drug Profile 97
EP-200 - Drug Profile 99
epacadostat - Drug Profile 100
everolimus - Drug Profile 102
FROST-450 - Drug Profile 107
GALE-301 - Drug Profile 108
GDC-0927 - Drug Profile 110
GSK-2636771 - Drug Profile 111
HO-3867 - Drug Profile 112
HuMax-TF-ADC - Drug Profile 113
INCB-54828 - Drug Profile 114
lenvatinib - Drug Profile 115
lurbinectedin - Drug Profile 119
mirvetuximab soravtansine - Drug Profile 122
MK-2206 - Drug Profile 124
Modi-1 - Drug Profile 127
Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer - Drug Profile 128
neratinib - Drug Profile 129
nintedanib - Drug Profile 133
onapristone ER - Drug Profile 138
ONCO-101 - Drug Profile 140
ONT-10 - Drug Profile 141
OPB-111001 - Drug Profile 143
patritumab - Drug Profile 144
Peptides to Inhibit GnRH II Receptor for Oncology - Drug Profile 146
pimasertib hydrochloride + voxtalisib - Drug Profile 147
sapanisertib - Drug Profile 149
SAR-408701 - Drug Profile 151
selinexor - Drug Profile 152
SERD-2 - Drug Profile 157
SNG-1153 - Drug Profile 158
talazoparib - Drug Profile 159
trametinib dimethyl sulfoxide + uprosertib - Drug Profile 162
zoptarelin doxorubicin - Drug Profile 164
Endometrial Cancer - Recent Pipeline Updates 166
Endometrial Cancer - Dormant Projects 247
Endometrial Cancer - Discontinued Products 250
Endometrial Cancer - Product Development Milestones 251
Featured News & Press Releases 251
Appendix 260
Methodology 260
Coverage 260
Secondary Research 260
Primary Research 260
Expert Panel Validation 260
Contact Us 260
Disclaimer 261

List of Tables

Number of Products under Development for Endometrial Cancer, H1 2015 13
Number of Products under Development for Endometrial Cancer - Comparative Analysis, H1 2015 14
Number of Products under Development by Companies, H1 2015 16
Number of Products under Development by Companies, H1 2015 (Contd..1) 17
Number of Products under Development by Companies, H1 2015 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2015 19
Comparative Analysis by Late Stage Development, H1 2015 20
Comparative Analysis by Clinical Stage Development, H1 2015 21
Comparative Analysis by Early Stage Development, H1 2015 22
Products under Development by Companies, H1 2015 23
Products under Development by Companies, H1 2015 (Contd..1) 24
Products under Development by Companies, H1 2015 (Contd..2) 25
Products under Investigation by Universities/Institutes, H1 2015 26
Endometrial Cancer - Pipeline by Acceleron Pharma, Inc., H1 2015 27
Endometrial Cancer - Pipeline by Aeterna Zentaris Inc., H1 2015 28
Endometrial Cancer - Pipeline by Ariad Pharmaceuticals, Inc., H1 2015 29
Endometrial Cancer - Pipeline by Arno Therapeutics, Inc., H1 2015 30
Endometrial Cancer - Pipeline by ArQule, Inc., H1 2015 31
Endometrial Cancer - Pipeline by AstraZeneca Plc, H1 2015 32
Endometrial Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 33
Endometrial Cancer - Pipeline by BioMarin Pharmaceutical Inc., H1 2015 34
Endometrial Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015 35
Endometrial Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2015 36
Endometrial Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 37
Endometrial Cancer - Pipeline by Eisai Co., Ltd., H1 2015 38
Endometrial Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H1 2015 39
Endometrial Cancer - Pipeline by Exelixis, Inc., H1 2015 40
Endometrial Cancer - Pipeline by Farmsintez, H1 2015 41
Endometrial Cancer - Pipeline by Galena Biopharma, Inc., H1 2015 42
Endometrial Cancer - Pipeline by Genentech, Inc., H1 2015 43
Endometrial Cancer - Pipeline by Genmab A/S, H1 2015 44
Endometrial Cancer - Pipeline by GlaxoSmithKline Plc, H1 2015 45
Endometrial Cancer - Pipeline by Gradalis Inc., H1 2015 46
Endometrial Cancer - Pipeline by ImmunoGen, Inc., H1 2015 47
Endometrial Cancer - Pipeline by Incyte Corporation, H1 2015 48
Endometrial Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 49
Endometrial Cancer - Pipeline by Merck & Co., Inc., H1 2015 50
Endometrial Cancer - Pipeline by Merck KGaA, H1 2015 51
Endometrial Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 52
Endometrial Cancer - Pipeline by Novartis AG, H1 2015 53
Endometrial Cancer - Pipeline by OncoHoldings, Inc., H1 2015 54
Endometrial Cancer - Pipeline by Oncothyreon Inc., H1 2015 55
Endometrial Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 56
Endometrial Cancer - Pipeline by Pharma Mar, S.A., H1 2015 57
Endometrial Cancer - Pipeline by Puma Biotechnology, Inc., H1 2015 58
Endometrial Cancer - Pipeline by Sanofi, H1 2015 59
Endometrial Cancer - Pipeline by Scancell Holdings Plc, H1 2015 60
Endometrial Cancer - Pipeline by Shenogen Pharma Group Ltd., H1 2015 61
Assessment by Monotherapy Products, H1 2015 62
Assessment by Combination Products, H1 2015 63
Number of Products by Stage and Target, H1 2015 65
Number of Products by Stage and Mechanism of Action, H1 2015 69
Number of Products by Stage and Route of Administration, H1 2015 72
Number of Products by Stage and Molecule Type, H1 2015 74
Endometrial Cancer Therapeutics - Recent Pipeline Updates, H1 2015 170
Endometrial Cancer - Dormant Projects, H1 2015 251
Endometrial Cancer - Dormant Projects (Contd..1), H1 2015 252
Endometrial Cancer - Dormant Projects (Contd..2), H1 2015 253
Endometrial Cancer - Discontinued Products, H1 2015 254